Duration of ADT After BCR in RP Patients Receiving Salvage RT
Introduction to ADT Duration
- The American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology guidelines recommend a minimum duration of ADT of 4-6 months when combined with salvage RT for patients with any high-risk features 1, 2
- The minimum duration of 4-6 months is based on three landmark randomized trials that demonstrated 40-60% improvement in freedom from clinical progression with ADT durations ranging from 4-6 months at minimum 1, 3
Minimum Duration: 4-6 Months
- ADT can be initiated either concurrently with salvage RT or up to 2 months prior to starting radiation, based on trial protocols 1, 2
- Shorter durations than 4 months have not been demonstrated to improve patient outcomes 2, 3
- All three trials showed survival advantages with concurrent ADT, with RTOG 9601 and NRG/RTOG 0534 SPPORT specifically demonstrating overall survival benefits 1, 3
Extended Duration: 18-24 Months for High-Risk Disease
- For patients with high-risk features, clinicians may extend ADT duration to 18-24 months, particularly for those with Grade Group 4-5, positive surgical margins, higher PSA at time of salvage RT, PSA doubling time ≤6 months, seminal vesicle involvement, or persistently detectable post-operative PSA 4, 2, 3
- Stratified analysis from RTOG 9601 demonstrated that longer-term ADT was associated with lower likelihood of progression and death specifically in patients with high-risk factors 4, 3
Clinical Decision Algorithm
- The American Urological Association recommends determining if the patient has ANY of the following high-risk features: PSA ≥0.7 ng/mL at time of BCR, Grade Group 4-5, PSADT ≤6 months, persistently detectable post-operative PSA, seminal vesicle involvement, or node-positive disease 1, 5
- If ANY high-risk features are present, offer ADT with salvage RT for a minimum of 4-6 months 1, 2
- If MULTIPLE high-risk features or Grade Group 4-5 are present, extend ADT to 18-24 months 4, 2, 3
Important Caveats
- PSA threshold considerations: for patients with PSA <0.7 ng/mL, PSA alone should not determine ADT use—other high-risk features must be considered 1, 5
- Margin status caveat: while positive surgical margins are listed as a high-risk feature, this is one of the more inconsistent risk indicators for ADT benefit 5
- Toxicity considerations: ADT increases acute grade 2 adverse events, hot flashes, hypertension, gynecomastia, and sexual dysfunction, but these quality-of-life impacts must be weighed against the mortality and metastasis benefits 2, 3
ADT Duration with Salvage Radiotherapy after Radical Prostatectomy
Definition of Biochemical Recurrence
- Biochemical recurrence is defined as a postoperative PSA ≥ 0.2 ng/mL confirmed on two separate measurements. Level 2 evidence (prospective cohort). 6, 7
High‑Risk Features Guiding Minimum ADT (4–6 months)
- Persistently detectable postoperative PSA (≥ 0.2 ng/mL on two measurements) is classified as a high‑risk feature that warrants at least 4–6 months of androgen‑deprivation therapy combined with salvage radiotherapy. Level 2 evidence (retrospective analysis). 6
PSA Doubling Time as Predictor of Extended ADT Benefit (18–24 months)
- A PSA doubling time ≤ 6 months identifies patients who derive the greatest reduction in progression and mortality when treated with extended (18–24 months) ADT, based on stratified analysis of a randomized trial. Level 1 evidence (randomized controlled trial). 8